GlaxoSmithKline reports return to profit in second quarter

British drugmaker GlaxoSmithKline posted net profit of more than £1.1 billion in the second quarter on Tuesday following a loss during the equivalent three-month period in 2010.

GSK said in a statement that earnings after tax stood at £1.106 billion (1.252 billion euros, $1.814 billion) in the quarter ending June 30 compared with a net loss of £304 million in the second quarter last year.

The company had fallen into a loss a year ago owing to exceptional legal charges linked to its former diabetes drug Avandia, which has been pulled from European shelves on fears that it increased the risk of heart attack and strokes.

"We have had a strong second quarter," GSK chief executive Andrew Witty said in the company's earnings statement.

"Going forward, we continue to apply sustained pressure to GSK's cost base to realise further savings, through improvements in areas such as support functions, supply chain and procurement efficiency."

GSK was rocked last September when the EU medicines regulator decided to pull Avandia off the shelves. Regulators also restricted its availability in the United States.

The EU decided to pull Avandia owing to concerns over its active substance rosiglitazone. It decided also to halt the sale of Glaxo's other diabetes drugs, Avandamet and Avaglim, since they too contained rosiglitazone.

Meanwhile sales of GSK's herpes treatment Valtrex have been hit by generic competition.

GSK added Tuesday that revenues declined by four percent to £6.72 billion in the second quarter.

add to favorites email to friend print save as pdf

Related Stories

GSK to take $3.4 bln Avandia legal charge

Jan 17, 2011

British drugs firm GlaxoSmithKline said Monday it expects to take a legal charge of £2.2 billion linked to its former blockbuster diabetes product Avandia, sparking a sharp drop in its shares.

Glaxo defends handling of Avandia heart risks

Feb 24, 2010

(AP) -- GlaxoSmithKline said Wednesday a Senate report criticizing its handling of heart risks with its diabetes drug Avandia "mischaracterizes and distorts" the company's record.

Taiwan's AU Optronics sees profit up 54.6 percent

Jul 28, 2010

Taiwan's AU Optronics Corp said Wednesday its net profit in the three months to June jumped 54.6 percent over the previous quarter, partly due to strong demand for high-priced items.

US restricts, EU bans controversial diabetes pill (Update)

Sep 23, 2010

(AP) -- European regulators ordered the diabetes drug Avandia off the market and the Food and Drug Administration placed stringent restrictions on its use in the United States, saying heart attack risks associated with the ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

16 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments